test44
https://www.cytel.com/blog/adaptive-designs-for-early-phase-development-are-we-asking-the-right-questions
May 3, 2022
In 2005, Pfizer launched a Phase 1 trial for the kinase inhibitor crizotinib. Six years later, it was approved, thanks..
Read article
test44
https://www.cytel.com/blog/inside-the-oncology-statistician-toolkit
February 9, 2017
In this blog, Adam Hamm, PhD, Director Biostatistics at Cytel shares some of the most important knowledge he uses..
Read article
test44
https://www.cytel.com/blog/case-study-blrm-oncology
test44
https://www.cytel.com/blog/an-introduction-to-blrm
August 31, 2016
Traditional rule-based approaches to dose escalation such as 3+3 are widely used in early clinical development. They..
Read article
test44
https://www.cytel.com/blog/how-does-tstatistic-stack-up-mtd
August 23, 2016
At the recent JSM meeting in Chicago, Cytel's Jim Bolognese presented the results of work he has conducted evaluating..
Read article
test44
https://www.cytel.com/blog/single-and-dual-agent-dose-escalation-webinar
July 21, 2016
Did you miss our webinar on Single and Dual Agent Dose escalation designs earlier in the year? In this blog..
Read article
test44
https://www.cytel.com/blog/bayesian-dose-escalation-designs-for-late-onset-toxicity
November 10, 2015
Last week Cytel joined forces with Sanofi/Genzyme to devote a full day of workshops and talks related to modern methods..
Read article
test44
https://www.cytel.com/blog/a-bayesian-industry-approach-to-phase-i-combination-trials-in-oncology
November 18, 2014
Statisticians and scientists at Novartis have been at the forefront of developing a new method in early phase oncology..
Read article
test44
https://www.cytel.com/blog/adaptive-designs-for-evidence-based-oncology-insights-from-the-experts
September 4, 2014
Imagine if we were to count the number of possible reasons that investigators might have for monitoring a biomarker..
Read article
